BFA Law is investigating Alignment Healthcare for potential securities fraud after a whistleblower lawsuit alleged the company misclassified expenses to inflate adjusted EBITDA, triggering a 16.7% stock decline on July 8, 2026.
A securities law firm is investigating Alignment Healthcare over whistleblower allegations that it misclassified $8-10 million of operating expenses as capital expenditures, turning a claimed $7-9 million loss into reported positive adjusted EBITDA of $1.3 million in 2024. The fresh litigation overhang on top of the July 8, 2026 drop of about 16.7% keeps pressure on the stock, though the underlying allegations are not new and the announcement is itself promotional.
Bleichmar Fonti & Auld LLP has launched an investigation into Alignment Healthcare, Inc. following allegations that the company misclassified $8 million to $10 million in operating expenses as capital expenditures. The whistleblower lawsuit claims these actions artificially inflated 2024 adjusted EBITDA to $1.3 million, masking a potential loss of $7 million to $9 million.
Law firm BFA announced on November 10, 2026 that it is investigating possible securities fraud after a whistleblower alleged the company misclassified $8-10 million in operating expenses as capital expenditures to inflate adjusted EBITDA and executive compensation.
The article reports that Alignment shares fell approximately 16.7% on July 8, 2026, when the whistleblower lawsuit alleging the EBITDA misclassification became public.